Concerns growing over government's stern measures

Concerns have mounted following the government's unilateral administrative measure to cancel the title of innovative pharmaceutical firms that have been caught providing illicit kickbacks or rebate to hospitals, which was announced on Wednesday.

In a statement, the Korea Pharmaceutical Manufacturers Association (KPMA) has called on the government to cancel the title when the innovative drug ...